文献速递前列腺癌

前列腺特异性膜抗原正电子发射断层扫描/计算机断层扫描与骨扫描在前列腺癌诊断时检测骨骼转移的个体内比较

Intra-individual comparison of prostate-specific membrane antigen positron emission tomography/computed tomography versus bone scan in detecting skeletal metastasis at prostate cancer diagnosis.
PubMed 文献 · BJU Int · 2023-11-09

本研究回顾性分析667例接受前列腺癌原发分期、并在1周内同时完成68Ga-PSMA PET/CT与99Tc全身骨扫描(WBBS)的患者。PSMA PET/CT总体检出明确骨骼转移的比例高于WBBS(10.3% vs 7.3%),且PSMA PET/CT导致分期上调更常见(P=0.001)。原发肿瘤SUVmax与PSMA PET/CT的分期上调相关(P=0.025)。

要点

  • PSMA PET/CT总体检出明确骨骼转移10.3%,WBBS为7.3%。
  • PSMA PET/CT较WBBS更常导致分期上调(P=0.001)。
  • 原发肿瘤SUVmax与PSMA PET/CT骨骼转移分期上调相关(P=0.025)。

核心结论

  • PSMA PET/CT较WBBS检出更多骨骼转移,导致更高的分期上调率,主要见于高危患者。
  • 原发肿瘤及转移灶的SUVmax与分期上调相关。

研究设计与样本

  • 前瞻性机构数据库的回顾性分析,纳入667例前列腺癌原发分期患者,均在1周内接受PSMA PET与WBBS检查。
  • 病灶由核医学医师判读为阴性、不确定或明确,转移负荷分为局部病变、寡转移(≤3处骨骼转移)和多转移(>3处骨骼转移)三组。

主要发现

  • 按风险分组,PSMA PET/CT检出明确骨骼转移在高危组为12% vs WBBS 9%,在中危组为4% vs 1%。
  • 两种扫描的骨骼转移检出总体分布有变化(P=0.003),在高危组(P=0.030)和低危组(P=0.018)内维持。
  • PSMA PET/CT导致分期上调较WBBS更常见(P=0.001)。
  • 原发肿瘤SUVmax与PSMA PET/CT骨骼转移分期上调相关(P=0.025),年龄与WBBS分期上调相关(P=0.021)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To compare the diagnostic performance and radiological staging impact of 68 Ga-prostate-specific membrane antigen positron emission tomography/computed tomography (PSMA PET/CT) compared to 99 Tc whole-body bone scan (WBBS) for the detection of skeletal metastasis in the primary staging of prostate cancer (PCa). PATIENTS AND METHODS: A prospective institutional database was retrospectively examined for patients who underwent both PSMA PET and WBBS within a 1 week interval for PCa primary staging. Lesions were categorised as 'negative', 'equivocal', or 'definite' based on nuclear medicine physician interpretation. Metastatic burden was characterised for each imaging modality according to three groups: (i) local disease (no skeletal metastases), (ii) oligometastatic disease (three or fewer skeletal metastases), or (iii) polymetastatic disease (more than three skeletal metastases). RESULTS: There were 667 patients included. The median (interquartile range) prostate-specific antigen level was 9.2 (6.2-16) ng/mL and 60% of patients were high risk according to a modified D'Amico risk classification. The overall distribution of skeletal metastasis detection changed across the two scans overall (P = 0.003), being maintained within high-risk (P = 0.030) and low-risk (P = 0.018) groups. PSMA PET/CT identified more definite skeletal metastases compared to WBBS overall (10.3% vs 7.3%), and according to risk grouping (high: 12% vs 9%, intermediate: 4% vs 1%). Upstaging was more common with PSMA PET/CT than WBBS (P = 0.001). The maximum standardised uptake value (SUVmax ) of the primary tumour was associated with upstaging of skeletal metastases on PSMA PET/CT (P = 0.025), while age was associated with upstaging on WBBS (P = 0.021). The SUVmax of the primary tumour and metastases were both higher according to extent of metastatic disease (P = 0.001 and P < 0.001, respectively). CONCLUSIONS: More skeletal metastases were detected with PSMA PET/CT than WBBS, resulting in a higher upstaging rate mostly in high-risk patients. The SUVmax of the primary tumour and metastases was associated with upstaging.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Shanmugasundaram R, Saad J, Heyworth A, et al. Intra-individual comparison of prostate-specific membrane antigen positron emission tomography/computed tomography versus bone scan in detecting skeletal metastasis at prostate cancer diagnosis. BJU Int. 2023. PMID: 37943964. doi:10.1111/bju.16115

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。